Charles River Laboratories International, Inc.
HealthcareNYSE:CRL · New York Stock Exchange
-$0.55 today
Vol 0.40M · Avg 0.88M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-4.6%
avg 12.8%
ROIC
8.4%
avg 6.9%
ROA
-2.0%
avg 4.6%
Analysis
ROIC is currently the strongest return metric at 8.4% versus its period average of 6.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James C. Foster | Chairman, President & Chief Executive Officer | $3.83M | — | 75 | $126,596.00 | 0.26% |
Birgit Girshick | CEO & Director | $1.77M | — | 56 | $36,013.00 | 0.07% |
Joseph W. LaPlume | Corporate Executive Vice President of Corporate Development & Strategy | $1.25M | — | 52 | $31,298.00 | 0.06% |
Victoria L. Creamer | Corporate Executive Vice President & Chief People Officer | $1.23M | — | 56 | $30,051.00 | 0.06% |
Glenn G. Coleman | Corporate Executive Vice President & Chief Financial Officer | $930,201.00 | — | 58 | $27,752.00 | 0.06% |
Michael Gunnar Knell | Corporate Senior Vice President & Chief Accounting Officer | $912,225.00 | — | 49 | $16,152.00 | 0.03% |
Julie Frearson | Corporate Senior Vice President & Chief Scientific Officer | — | — | — | — | — |
Mark Mintz | Corporate EVP, Chief Information Officer & Global Shared Services | — | — | 52 | $9,546.00 | 0.02% |
Todd Spencer | Corporate Vice President of Investor Relations | — | — | — | — | — |
Amy Cianciaruso | Corporate Senior Vice President, Chief Communications Officer & Government Relations | — | — | — | — | — |
Kerry Dailey | Corporate Senior VP & Chief Legal Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$4,363.50
Sells
3
$251,584.00
Net Sentiment
$247,220.50
Net selling
Most Active
LaPlume Joseph W
4 transactions
Analysis
Insiders reported 1 buys worth $4,363.50 and 3 sells worth $251,584.00 over the last 12 months. That adds up to net selling of $247,220.50. LaPlume Joseph W was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +15.9% | +11.2% (15yr)1 analysts |
| Revenue | N/A | N/A | +6.5% | +7.9% (15yr)5 analysts |
| Net Income | N/A | N/A | +15.3% | +11.4% (15yr)5 analysts |
| EBIT | N/A | N/A | +7.6% | +7.1% (15yr)5 analysts |
Analysis
Recent growth has been strongest in EPS at +15.9% over three years. Forward estimates point to Net Income at +11.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Penumbra, Inc.
NYSE:PEN
$12.54B
Revvity, Inc.
NYSE:RVTY
$11.12B
Baxter International Inc.
NYSE:BAX
$10.77B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
Qiagen N.V.
NYSE:QGEN
$7.64B
Avantor, Inc.
NYSE:AVTR
$6.41B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.08B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages CRL?
Charles River Laboratories International, Inc. (CRL) lists 11 active executives. The top listed executive is Joseph W. LaPlume, Corporate Executive Vice President of Corporate Development & Strategy.
Are CRL insiders buying or selling?
Recent insider activity shows net buying of $23.28M.
Explore More
Continue the stock analysis
Jump to another research area for this company.